Newamsterdam Pharma Stock Analysis
| NAMS Stock | 20.20 0.08 0.40% |
NewAmsterdam Pharma is undervalued with Real Value of 22.69 and Target Price of 25.16. The main objective of NewAmsterdam Pharma stock analysis is to determine its intrinsic value, which is an estimate of what NewAmsterdam Pharma is worth, separate from its market price. There are two main types of NewAmsterdam Pharma's stock analysis: fundamental analysis and technical analysis.
The NewAmsterdam Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. NewAmsterdam Pharma is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. NewAmsterdam Stock trading window is adjusted to America/New York timezone.
NewAmsterdam |
NewAmsterdam Stock Analysis Notes
About 84.0% of the company shares are owned by institutional investors. The book value of NewAmsterdam Pharma was now reported as 4.11. The company recorded a loss per share of 2.21. NewAmsterdam Pharma had not issued any dividends in recent years. The entity had 1:1 split on the 23rd of November 2022. To find out more about NewAmsterdam Pharma contact FACC Facp at 31 35 206 2971 or learn more at https://www.newamsterdampharma.com.NewAmsterdam Pharma Quarterly Total Revenue |
|
NewAmsterdam Pharma Investment Alerts
| NewAmsterdam Pharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 12.76 M. Net Loss for the year was (160.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors andor HeFH |
NewAmsterdam Pharma Upcoming and Recent Events
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
NewAmsterdam Largest EPS Surprises
Earnings surprises can significantly impact NewAmsterdam Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-07 | 2024-06-30 | -0.58 | -0.41 | 0.17 | 29 | ||
2023-11-13 | 2023-09-30 | -0.8731 | -0.5642 | 0.3089 | 35 | ||
2024-11-06 | 2024-09-30 | -0.5 | -0.18 | 0.32 | 64 |
NewAmsterdam Pharma Environmental, Social, and Governance (ESG) Scores
NewAmsterdam Pharma's ESG score is a quantitative measure that evaluates NewAmsterdam Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of NewAmsterdam Pharma's operations that may have significant financial implications and affect NewAmsterdam Pharma's stock price as well as guide investors towards more socially responsible investments.
NewAmsterdam Stock Institutional Investors
| Shares | Polar Capital Holdings Plc | 2024-06-30 | 1 M | Gmt Capital Corp | 2024-06-30 | 891.8 K | Deerfield Management Co | 2024-06-30 | 869.2 K | Artal Group S A | 2024-06-30 | 800 K | Pictet Asset Manangement Sa | 2024-06-30 | 683.7 K | Avidity Partners Management Lp | 2024-06-30 | 559.3 K | Woodline Partners Lp | 2024-06-30 | 483.4 K | Affinity Asset Advisors, Llc | 2024-09-30 | 472.4 K | Decheng Capital Llc | 2024-06-30 | 400 K | Fcpm Iii Services Bv | 2024-06-30 | 11.8 M | Bain Capital Life Sciences Investors, Llc | 2024-06-30 | 10.5 M |
NewAmsterdam Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.29 B.NewAmsterdam Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.55) | (0.52) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.61) | (0.58) |
Management Efficiency
NewAmsterdam Pharma has return on total asset (ROA) of (0.2927) % which means that it has lost $0.2927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4737) %, meaning that it created substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to gain to -0.52 in 2024. At this time, NewAmsterdam Pharma's Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 17.1 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 264.2 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.51 | 6.34 | |
| Tangible Book Value Per Share | 3.51 | 5.46 | |
| Enterprise Value Over EBITDA | (2.96) | (2.81) | |
| Price Book Value Ratio | 2.88 | 3.02 | |
| Enterprise Value Multiple | (2.96) | (2.81) | |
| Price Fair Value | 2.88 | 3.02 | |
| Enterprise Value | 489.9 M | 514.4 M |
NewAmsterdam Pharma has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Operating Margin (0.86) | Beta (0) | Return On Assets (0.29) | Return On Equity (0.47) |
Technical Drivers
As of the 23rd of November, NewAmsterdam Pharma secures the Risk Adjusted Performance of 0.0903, downside deviation of 3.68, and Mean Deviation of 2.33. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NewAmsterdam Pharma, as well as the relationship between them. Please verify NewAmsterdam Pharma jensen alpha and downside variance to decide if NewAmsterdam Pharma is priced some-what accurately, providing market reflects its recent price of 20.2 per share. Given that NewAmsterdam Pharma has jensen alpha of 0.1653, we recommend you to check NewAmsterdam Pharma's last-minute market performance to make sure the company can sustain itself at a future point.NewAmsterdam Pharma Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. NewAmsterdam Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for NewAmsterdam Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
NewAmsterdam Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewAmsterdam Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewAmsterdam Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NewAmsterdam Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NewAmsterdam Pharma Predictive Daily Indicators
NewAmsterdam Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NewAmsterdam Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
NewAmsterdam Pharma Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 15th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 28th of October 2024 Other Reports | ViewVerify | |
8K | 18th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
NewAmsterdam Pharma Forecast Models
NewAmsterdam Pharma's time-series forecasting models are one of many NewAmsterdam Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NewAmsterdam Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About NewAmsterdam Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NewAmsterdam Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NewAmsterdam shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NewAmsterdam Pharma. By using and applying NewAmsterdam Stock analysis, traders can create a robust methodology for identifying NewAmsterdam entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (12.56) | (13.18) | |
| Operating Profit Margin | (12.99) | (13.63) | |
| Net Loss | (13.86) | (14.56) |
Current NewAmsterdam Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. NewAmsterdam analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. NewAmsterdam analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 25.16 | Strong Buy | 9 | Odds |
Most NewAmsterdam analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand NewAmsterdam stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of NewAmsterdam Pharma, talking to its executives and customers, or listening to NewAmsterdam conference calls.
NewAmsterdam Stock Analysis Indicators
NewAmsterdam Pharma stock analysis indicators help investors evaluate how NewAmsterdam Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading NewAmsterdam Pharma shares will generate the highest return on investment. By understating and applying NewAmsterdam Pharma stock analysis, traders can identify NewAmsterdam Pharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 467.7 M | |
| Common Stock Shares Outstanding | 82.2 M | |
| Total Stockholder Equity | 288.4 M | |
| Tax Provision | 27 K | |
| Property Plant And Equipment Net | 91.8 K | |
| Cash And Short Term Investments | 340.4 M | |
| Cash | 340.4 M | |
| Accounts Payable | 16.9 M | |
| Net Debt | -340.4 M | |
| 50 Day M A | 17.8304 | |
| Total Current Liabilities | 45.3 M | |
| Other Operating Expenses | 183.2 M | |
| Non Current Assets Total | 278.1 K | |
| Non Currrent Assets Other | 16.3 K | |
| Stock Based Compensation | 22.3 M |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.